LMed 93
LMed 93 is an antiviral agent. LMed 93 inhibits the activity of influenza A virus RNA polymerase. LMed 93 suppresses viral RNA synthesis. LMed 93 inhibits the replication of influenza A viruses H5N1 and H1N1. LMed 93 can be used for the research of influenza A virus infections (H1N1, H5N1).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C19H13ClO5
- Masse moléculaire:356.76
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
Description
IC50 & Target
[1]|
RNA Polymerase |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDCK-II | EC50 |
5.66 μM
|
Inhibition of Influenza A virus H1N1 (A/WSN/1933) replication in MDCK II cells assessed via Focus Forming Assay after 24 h incubation with simultaneous virus inoculation and reagent treatment.
Inhibition of Influenza A virus H1N1 (A/WSN/1933) replication in MDCK II cells assessed via Focus Forming Assay after 24 h incubation with simultaneous virus inoculation and reagent treatment.
|
42485991 |
| MDCK-II | EC50 |
9.13 μM
|
Inhibition of Influenza A virus H5N1 (A/Thailand/KAN-1/2004) replication in MDCK II cells assessed via Focus Forming Assay after 24 h incubation with simultaneous virus inoculation and reagent treatment.
Inhibition of Influenza A virus H5N1 (A/Thailand/KAN-1/2004) replication in MDCK II cells assessed via Focus Forming Assay after 24 h incubation with simultaneous virus inoculation and reagent treatment.
|
42485991 |
In Vitro
LMed 93 (0.4-350 μM; 24 h) potently inhibits Influenza A virus H1N1 replication in MDCK II cells with an EC50 of 5.66 μM and a high selectivity index of >49.52[1].
LMed 93 (4.375-70 μM) inhibits Influenza A virus H5N1 replication in MDCK II cells with an EC50 of 9.13 μM and a high selectivity index of >30.71[1].
LMed 93 (70 μM) potently inhibits Influenza A virus H1N1 replication in MDCK II cells during early and intermediate infection stages (1 hpi and 3 hpi) but has reduced efficacy at late stages (6 hpi)[1].
LMed 93 (70 μM) significantly reduces viral genomic RNA (vRNA) levels in H1N1-infected MDCK II cells at all post-infection time points tested, without altering viral mRNA levels[1].
LMed 93 (35-70 μM; 20 h) modestly inhibits Influenza A virus RNA polymerase activity in MDCK II cells, reducing reporter activity by 38.7% at 35 μM and 53.7% at 70 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDCK II cells
-
Concentration:70 μM
-
Incubation Time:8 h (1 hpi to 9 hpi); 6 h (3 hpi to 9 hpi); 3 h (6 hpi to 9 hpi)
-
Result:Reduced M1 vRNA levels by 82% (n-fold = 0.18) at 1 hpi.
Reduced M1 vRNA levels by 78% (n-fold = 0.22) at 3 hpi.
Reduced M1 vRNA levels by 60% (n-fold = 0.40) at 6 hpi.
Did not significantly reduce M1 or PB1 mRNA levels at any time point.
Chemical Information
-
Masse moléculaire 356.76
-
Formule C19H13ClO5
-
SMILES
ClC1=CC=C(OC(C(C(/C=C/C2=CC(OC)=C(O)C=C2)=O)=C3)=O)C3=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
LMed 93 Related Classifications
HY-187427 Related Classifications
Powered by Bioz
Keywords